Oryzon Genomics S.A. (0RDB.L)

EUR 1.6

(-4.88%)

Market Cap (In EUR)

103.4 Million

Revenue (In EUR)

15.66 Million

Net Income (In EUR)

-3.7 Million

Avg. Volume

2518.00

Currency
EUR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.598-2.395
PE
-
EPS
-
Beta Value
0.646
ISIN
ES0167733015
CUSIP
E7S54Q107
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Dr. Carlos Manuel Buesa Arjol
Employee Count
-
Website
https://www.oryzon.com
Ipo Date
2016-12-15
Details
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.